11 Analysts Have This to Say About ACADIA Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 11 analysts have published their opinions on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock, with an average price target of $25.33, implying an upside from the current price of $24.475. The average price target has increased by 17.27% over the past month.
June 14, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
11 analysts have published opinions on ACADIA Pharmaceuticals stock in the past 3 months, with an average price target of $25.33, implying an upside from the current price of $24.475.
The average price target of $25.33 from 11 analysts implies an upside potential for ACADIA Pharmaceuticals stock. This positive outlook, combined with the fact that the average price target has increased by 17.27% over the past month, suggests that the stock is likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100